## <u>Home About Life Time Corporate Social Responsibility News Releases</u>

## **Eiger BioPharmaceuticals to Participate in Investor Conferences**

PALO ALTO, Calif., Sept. 25, 2018 / PRNewswire -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that David Cory, President and CEO, will present at two investor conferences in October in New York City.

- Cantor Fitzgerald 4<sup>th</sup> Annual Healthcare Conference at the Intercontinental New York Barclay. Corporate presentation on October 1, 2018, 4:40 PM ET. Eiger will host one-on-one meetings.
- Ladenburg Thalmann 4<sup>th</sup> Annual Healthcare Conference at the Sofitel New York City. Corporate Presentation on October 2, 2018, 9:00 AM ET. Eiger will host one-on-one meetings.

A live webcast of both presentations will be available on the Eiger BioPharmaceuticals website at <a href="https://www.eigerbio.com">www.eigerbio.com</a> under the "Investors" tab. A replay of the webcasts will be available approximately one hour following the completion of the live event.

## About Eiger

Eiger is a clinical-stage, biopharmaceutical company focused on accelerating the development and commercialization of targeted therapies for rare and ultra-rare diseases. We innovate by developing well-characterized drugs acting on newly identified or novel targets in rare diseases. Our mission is to systematically reduce the time and cost of the drug development process to more rapidly deliver important medicines to patients. Lonafarnib is our lead compound advancing into Phase 3 with a single, pivotal trial to treat HDV to initiate by the end of the year. Lonafarnib is also advancing toward an NDA for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) in 2019. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Investors: Ingrid Choong, PhD

Email: ichoong@eigerbio.com / Phone: 1-650-619-6115

SOURCE Eiger BioPharmaceuticals, Inc.